MedTrace Logo

Liver Function Assessment - Feasibility and Dosing Study

NCT02516319 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2016-01-15

No results posted yet for this study

Summary

The purpose of this study is to 1) determine the feasibility of using Cardiox Liver Function Assessment System (LFA) to measure indocyanine green (ICG) clearance; 2) determine an adequate dose based on LFA technology and 3) determine an adequate time period for LFA determination.

Conditions

  • Hepatic Failure

Interventions

DRUG

ICG Dye

Sponsors & Collaborators

  • Cardiox Corporation

    lead INDUSTRY

Principal Investigators

  • Michael W Jopling, M.D · Cardiox Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2016-01-31
Completion
2016-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02516319 on ClinicalTrials.gov